The article presents the new recommendation in the administration of the tissue plasminogen activator (tPA) for the treatment of an ischemic stroke up to four and a half hours after the onset of symptoms. It suggests the use of tPA therapy at the first hour of a stroke for better results....
Using an ambulance that included a computed tomography (CT) scanner, point-of-care laboratory, telemedicine connection and a specialized prehospital stroke team resulted in decreased time to treatment for ischemic stroke, according to a study in the April 23/30 issue of JAMA, a neurology theme ...
A tool widely used by doctors to help determine who needs clot-busting therapy after a stroke has some missing pieces, according to new research that suggests adding a few simple tests could help improve treatment for people who have less common strokes
ent: time is brain. Stroke treatment: time is brain.Stroke treatment: time is brain.EBSCO_AspLancet
Intravenous Tissue-Type Plasminogen Activator for Treatment of Acute Stroke: The Standard Treatment with Alteplase to Reverse Stroke (STARS) Study Tissue-type plasminogen activator (tPA) is the only therapy for acute ischemic stroke approved by the Food and Drug Administration.To assess the safety pro...
Time to reperfusion and treatment effect for acute ischemic stroke. JAMA Neurol. 2016;73(2):190-196.ArticlePubMedGoogle ScholarCrossref 11. Menon BK, Sajobi TT, Zhang Y, et al. Analysis of workflow and time to treatment on thrombectomy outcome in the Endovascular Treatment for Small Core...
Although the number of people affected by stroke is large, the public's awareness of stroke symptoms and the need for immediate treatment evaluation is poor (Hickenbottom & Morgenstern, 2002; Williams, Bruno, Rouch, & Marriott, 1997). The five most common warning signs of stroke are (a) su...
All patients admitted for a recurrent ischemic stroke or TIA were prospectively registered. The etiology was determined according to the TOAST classification. The risk factors and cardiovascular treatment at the time of the recurrence were recorded. A total of 168 patients were evaluated. Most of ...
While waiting for the next breakthrough drug in acute stroke treatment, it is equally important to allocate considerable effort to find approaches to address the limitations of the only FDA-approved stroke therapy. 展开 关键词: Tissue plasminogen activator Hemorrhage Vasculature Blood-brain barrier ...
Despite its effectiveness in improving neurological outcomes, the majority of patients with ischemic stroke are not treated with rtPA, largely because they arrive after the currently approved 3-hour time limit for administration of the medication. One of the potential approaches to increase treatment ...